Clinical trials in Fort Worth, TX

85 recruiting studies have a site in or near Fort Worth, TX, Texas.

Top conditions here

All conditions

Showing 40 of 85 studies

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Abilene, TX · Amarillo, TX · Austin, TX · +1147 more sites

RecruitingPhase 2NCT06317662

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Sponsor: National Cancer Institute (NCI)

Austin, TX · Corpus Christi, TX · Dallas, TX · +112 more sites

RecruitingPhase 3NCT07404865

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

Sponsor: Vor Biopharma

Allen, TX · Amarillo, TX · +44 more sites

RecruitingPhase 2NCT07683325

NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease

Sponsor: Agomab Spain S.L.U.

Fort Worth, TX · Georgetown, TX · +3 more sites

RecruitingPhase 3NCT06617325

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Sponsor: UCB Biopharma SRL

Bellaire, TX · El Paso, TX · Fort Worth, TX · +60 more sites

RecruitingPhase 3NCT07177352

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Sponsor: Hoffmann-La Roche

Beaumont, TX · Brownsville, TX · Dallas, TX · +65 more sites

RecruitingPhase 2NCT07697456

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Sponsor: AbbVie

Bellaire, TX · Fort Worth, TX · Garland, TX · +57 more sites

RecruitingPhase 3NCT06935370

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

Sponsor: Boehringer Ingelheim

Amarillo, TX · Beaumont, TX · +86 more sites

RecruitingPhase 3NCT07028853

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Sponsor: Pfizer

Dallas, TX · +124 more sites

RecruitingPhase 3NCT07064473

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Sponsor: Boehringer Ingelheim

Austin, TX · Brownsville, TX · +205 more sites

RecruitingPhase 2NCT07610473

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

Sponsor: Draig Therapeutics Ltd

DeSoto, TX · Fort Worth, TX · +21 more sites

RecruitingPhase 3NCT06136559

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Sponsor: Merck Sharp & Dohme LLC

Austin, TX · Fort Worth, TX · San Antonio, TX · +46 more sites

RecruitingPhase 3NCT06312176

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Sponsor: Merck Sharp & Dohme LLC

Dallas, TX · +43 more sites

RecruitingPhase 3NCT06952504

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Sponsor: Merck Sharp & Dohme LLC

Fort Worth, TX · Houston, TX · San Antonio, TX · +50 more sites

RecruitingPhase 3NCT06966700

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Sponsor: Merck Sharp & Dohme LLC

Abilene, TX · Dallas, TX · +61 more sites

RecruitingPhase 3NCT06989112

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Sponsor: AstraZeneca

Austin, TX · Fort Worth, TX · Houston, TX · +60 more sites

RecruitingPhase 3NCT07144280

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Sponsor: Pfizer

Abilene, TX · Allen, TX · Amarillo, TX · +238 more sites

RecruitingPhase 2NCT07187531

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

Sponsor: SAb Biotherapeutics, Inc.

Dallas, TX · Fort Worth, TX · Houston, TX · +19 more sites

RecruitingPhase 3NCT07216703

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Sponsor: Merck Sharp & Dohme LLC

Fort Worth, TX · Houston, TX · The Woodlands, TX · +27 more sites

RecruitingPhase 2NCT07023289

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

Sponsor: AbbVie

Austin, TX · Fort Worth, TX · Grapevine, TX · +19 more sites

RecruitingPhase 2NCT07186101

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

Sponsor: Eli Lilly and Company

Cedar Park, TX · Dallas, TX · Fort Worth, TX · +37 more sites

RecruitingPhase 3NCT07222566

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor: Pfizer

Abilene, TX · Allen, TX · Amarillo, TX · +223 more sites

RecruitingPhase 2NCT07415044

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

Sponsor: Eli Lilly and Company

Fort Worth, TX · Garland, TX · Houston, TX · +49 more sites

RecruitingPhase 3NCT04844606

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

Sponsor: Eli Lilly and Company

Fort Worth, TX · +10 more sites

RecruitingPhase 3NCT05509777

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Sponsor: Eli Lilly and Company

Fort Worth, TX · +14 more sites

RecruitingPhase 1 / Phase 2NCT05579366

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Sponsor: Genmab

Abilene, TX · Austin, TX · Dallas, TX · +34 more sites

RecruitingPhase 2NCT07410507

A Study of Brenipatide in Adult Participants With Schizophrenia

Sponsor: Eli Lilly and Company

DeSoto, TX · Fort Worth, TX · +30 more sites

RecruitingPhase 3NCT06790693

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Sponsor: Hoffmann-La Roche

Fort Worth, TX · Spring, TX · +60 more sites

RecruitingPhase 3NCT07228832

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Sponsor: Summit Therapeutics

Dallas, TX · Fort Worth, TX · +109 more sites

RecruitingPhase 1NCT03816345

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Sponsor: National Cancer Institute (NCI)

Dallas, TX · Fort Worth, TX · +48 more sites

RecruitingPhase 1NCT06840886

A Study of PHST001 in Advanced Solid Tumors

Sponsor: Pheast Therapeutics

Fort Worth, TX · Houston, TX · Irving, TX · +17 more sites

RecruitingPhase 3NCT07723248

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

Sponsor: ORIC Pharmaceuticals

Dallas, TX · Fort Worth, TX · Houston, TX · +8 more sites

RecruitingPhase 1NCT06270706

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Sponsor: Pliant Therapeutics, Inc.

Austin, TX · Fort Worth, TX · Houston, TX · +13 more sites

RecruitingPhase 3NCT07221851

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

Sponsor: Ascendis Pharma A/S

Edinburg, TX · Fort Worth, TX · San Antonio, TX · +20 more sites

RecruitingPhase 3NCT07361497

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Sponsor: Bristol-Myers Squibb

Amarillo, TX · Austin, TX · Denton, TX · +35 more sites

RecruitingNot applicableNCT07688720

Transcutaneous Auricular Neurostimulation (tAN) for Premenstrual Dysphoric Disorder (PMDD) and Perimenopause

Sponsor: Texas Christian University

Fort Worth, TX

RecruitingPhase 3NCT05646862

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Sponsor: Hoffmann-La Roche

Amarillo, TX · Dallas, TX · El Paso, TX · +36 more sites

RecruitingPhase 3NCT06819891

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Sponsor: Hoffmann-La Roche

Dallas, TX · Fort Worth, TX · Garland, TX · +58 more sites

RecruitingPhase 1NCT07277413

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Sponsor: IDEAYA Biosciences

Fort Worth, TX · Houston, TX · +20 more sites

RecruitingPhase 3NCT05923073

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

Sponsor: Janssen Research & Development, LLC

Fort Worth, TX · +13 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.